Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

NCT05608785 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER_GOV

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal-junction Cancer

Interventions

DRUG: IBI315
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: TST001
DRUG: TQB2450
DRUG: Anrotinib

Sponsor

Henan Cancer Hospital